Title: microRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Solid Cancers
Patent Number: 8,148,069
Filed: Jan. 3, 2007
Silence Therapeutics has scored a victory in its efforts to defend its intellectual property estate, announcing this week that the US Patent and Trademark Office has upheld the validity of four patents related to the design of RNAi molecules.
Title: Oncogenic ALL-1 Fusion Proteins for Targeting Drosha-Mediated microRNA Processing
Patent Number: 8,053,186
Filed: June 13, 2008
Inventor: Carlo Croce, Ohio State University
The patent, EP1633890, is part of the so-called Zamore IP estate and claims rules for designing RNAi molecules with improved potency and fewer off-target effects.
Bioethicists disagree with a research team's decision to allow the return of risk results for adult-onset conditions from a newborn sequencing project, according to Reuters.
Alterations to particular gene may enable the Quechua of Peru to better tolerate high-altitude life, Ars Technica reports.
Nature News reports that additional South Korean researchers have included the names of children on scientific papers when they did not contribute to the work.
In PLOS this week: statistical approach to prioritize rare variant searches, gene expression alterations in chronic obstructive pulmonary disease, and more.